Immunotherapy combo shows promise against tough head and neck cancers

NCT ID NCT05213884

Completed Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This study tested a new treatment approach for people with advanced head and neck cancer that cannot be removed by surgery. The treatment combined the immunotherapy drug camrelizumab with chemotherapy and radiation, followed by camrelizumab alone. The goal was to see if this combination could help control the cancer and improve survival. The study included 39 adults with stage III or IV squamous cell carcinoma of the head and neck.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400030, China
Chongqing University Three Gorges Hospital

Wanzhou, Chongqing Municipality, 404100, China
The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, 646000, China

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA